NEUROCRINE BIOSCNCE (NB3 BE) stock market data APIs
€123.4857
0(0%)
as of November 5, 2025
Try our APIs with
free plan!
NEUROCRINE BIOSCNCE Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for NB3.BE.
Prev. Close
123.4857
Open
123.4857
High
123.4857
Low
123.4857
52 wk Range
77-146.95
Market Cap
6 691 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get NEUROCRINE BIOSCNCE data using free add-ons & libraries
Get NEUROCRINE BIOSCNCE Fundamental Data
NEUROCRINE BIOSCNCE Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-28
- EPS/Forecast: 2.07
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
NEUROCRINE BIOSCNCE News
New
What Makes Neurocrine (NBIX) a New Strong Buy Stock
Neurocrine Biosciences (NBIX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimate...
Alnylam Stock Has Almost Doubled In 2025. But It Took A Hit On Earnings.
Alnylam stock took a hit Thursday after the biotech company said it received a subpoena from the U.S. government related to its four drugs. Continue Reading View Comments
Neurocrine Biosciences Inc (NBIX) Q3 2025 Earnings Call Highlights: Strong Sales Growth and ...
This article first appeared on GuruFocus. Net Product Sales: $790 million, reflecting 28% year-over-year growth. CRENESSITY Sales: Grew from $53 million in Q2 to $98 million in Q3. INGREZZA Sales: Ne...
Alnylam Stock Has Already Doubled In 2025. But It Took A Hit On Earnings.
Alnylam stock took a hit Thursday after the biotech company said it received a subpoena from the U.S. government related to its four drugs. Continue Reading View Comments
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
